Deep Dive: R&D Innovation
In this issue of Deep Dive we look at innovation in pharma R&D, asking how can pharmaceutical companies change up the development model with new strategies and technologies to cut waste and ensure the best medicines get to the patients that can benefit from them.
There’s also an additional focus on rare disease patients and how to best meet their needs, plus expert input from IDEA Pharma, Havas Lynx Faze, Johnson & Johnson, AstraZeneca, Alexion and Spire Health, as well as rare disease advocates Seth Rotberg and Ana Velosa.
Reimagining the future of healthcare
Johnson & Johnson Innovation’s William Hait talks about how the company is aiming to change the trajectory of human health through new approaches to R&D
Company Profile: IDEA pharma
IDEA Pharma on identifying as many paths to market as possible around phase 2, and not getting stuck on a ‘conveyor belt’ to inadequate phase 3 trial results
Innovating in clinical trial recruitment
Havas Lynx Faze discuss how talking to patients could prove to be a huge innovation in patient recruitment for clinical studies
Precision medicine: the next steps
AstraZeneca’s Ruth March talks about how precision medicine has changed and how it will continue to evolve in the near future
Realising the potential of wearable tech
Spire Health on how it is addressing the key problems with using wearable tech in clinical trials, such as usability and accuracy
A lifeline for rare disease patients
Sean Richardson and Charles de Wet on how Alexion are tackling the challenges in developing orphan drugs
Living with LHON: Adapting to sight loss at 15 years old
When faced with a devastating diagnosis, a family has two choices – to give up or make it their mission to adapt and carry on
How pharma can support doctors who treat rare diseases
Where do doctors see patients with rare diseases, how do they keep up with treatment advances and what can pharmaceutical companies do to help?
The patient perspective on advocacy
Partnership manager at Inspire Seth Rotberg talks about learning to live with a rare disease and his passion to help others do the same
Strength in numbers: Because having a rare disease isn’t rare
Global Genes’ Nicole Boice about why rare diseases need to be a global priority, and why she hopes her own organisation is heading towards obsolescence
• Read Deep Dive: R&D Innovation in full
pharmaphorum’s digital magazine Deep Dive provides objective, issue-driven views, analysis, high-level interviews and unique research for pharmaceutical companies, biotech firms and the wider healthcare sector.
In 2019 Deep Dive will have special focuses on disruptive technologies in pharma, R&D innovation, market access & commercialisation, oncology, sales & marketing innovation, digital health and patient engagement. Subscribe to future issues of Deep Dive.